These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12136423)

  • 1. Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor.
    Ogawa T; Takayama K; Takakura N; Kitano S; Ueno H
    Cancer Gene Ther; 2002 Aug; 9(8):633-40. PubMed ID: 12136423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.
    Takayama K; Ueno H; Nakanishi Y; Sakamoto T; Inoue K; Shimizu K; Oohashi H; Hara N
    Cancer Res; 2000 Apr; 60(8):2169-77. PubMed ID: 10786681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid tumor development and potent vascularization are independent events in carcinoma producing FGF-1 or FGF-2.
    Billottet C; Janji B; Thiery JP; Jouanneau J
    Oncogene; 2002 Nov; 21(53):8128-39. PubMed ID: 12444548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms.
    Auguste P; Gürsel DB; Lemière S; Reimers D; Cuevas P; Carceller F; Di Santo JP; Bikfalvi A
    Cancer Res; 2001 Feb; 61(4):1717-26. PubMed ID: 11245488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor.
    Balbay MD; Pettaway CA; Kuniyasu H; Inoue K; Ramirez E; Li E; Fidler IJ; Dinney CP
    Clin Cancer Res; 1999 Apr; 5(4):783-9. PubMed ID: 10213213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
    Haspel HC; Scicli GM; McMahon G; Scicli AG
    Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer.
    Takahashi Y; Cleary KR; Mai M; Kitadai Y; Bucana CD; Ellis LM
    Clin Cancer Res; 1996 Oct; 2(10):1679-84. PubMed ID: 9816116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.
    Giavazzi R; Sennino B; Coltrini D; Garofalo A; Dossi R; Ronca R; Tosatti MP; Presta M
    Am J Pathol; 2003 Jun; 162(6):1913-26. PubMed ID: 12759248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
    Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
    Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
    Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
    Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
    Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
    Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.
    Siemeister G; Schirner M; Weindel K; Reusch P; Menrad A; Marmé D; Martiny-Baron G
    Cancer Res; 1999 Jul; 59(13):3185-91. PubMed ID: 10397264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
    Joseph IB; Isaacs JT
    Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity in human glioma cell lines.
    Ke LD; Shi YX; Im SA; Chen X; Yung WK
    Clin Cancer Res; 2000 Jun; 6(6):2562-72. PubMed ID: 10873113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of vascular endothelial growth factor induces cell transformation in cooperation with fibroblast growth factor 2.
    Guerrin M; Scotet E; Malecaze F; Houssaint E; Plöuet J
    Oncogene; 1997 Jan; 14(4):463-71. PubMed ID: 9053843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.
    Jia H; Jezequel S; Löhr M; Shaikh S; Davis D; Soker S; Selwood D; Zachary I
    Biochem Biophys Res Commun; 2001 Apr; 283(1):164-73. PubMed ID: 11322784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.